Supply Chain Intelligence

Crinetics Pharmaceuticals, Inc. Supply Chain

CRNX supply chain intelligence for Crinetics Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CRNX ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

6Suppliers
13Customers
3Debt Items
20Related Chains

Crinetics Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
BIOLOGICS BIOLOGICS 90% An enrollment form is an official document containing both HCP and patient consent, submitted to CrinetiCARE or specialty pharmacies (Orsini or Biologics) to initiate a patient on Palsonify.
JEFF-KNIGHT JEFF-KNIGHT 90% On April 10, 2026, the Company entered into an Independent Consultant Agreement (the “Consulting Agreement”) with Mr. Knight, pursuant to which Mr. Knight agreed to provide certain services to the Company
ORSINI ORSINI 90% An enrollment form is an official document containing both HCP and patient consent, submitted to CrinetiCARE or specialty pharmacies (Orsini or Biologics) to initiate a patient on Palsonify.
RADIONETICS-ONCOLOGY-INC RADIONETICS-ONCOLOGY-INC 90% we entered into a Collaboration and License Agreement with Radionetics, or the Radionetics License, granting Radionetics an exclusive world-wide license to certain targets for the development of radi…
SANWA-KAGAKU-KENKYUSHO-CO-LTD SANWA-KAGAKU-KENKYUSHO-CO-LTD 90% In February 2022, we entered into the SKK License, pursuant to which we granted SKK an exclusive license to develop and commercialize paltusotine in Japan. Under the SKK License, SKK is responsible f…
OHIO-UNIVERSITY OHIO-UNIVERSITY 80% In May 2026, Crinetics entered into an exclusive license agreement with Ohio University to develop an early preclinical growth hormone receptor antagonist for the treatment of acromegaly.

Crinetics Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
CRINETICARE CRINETICARE 90% An enrollment form is an official document containing both HCP and patient consent, submitted to CrinetiCARE or specialty pharmacies (Orsini or Biologics) to initiate a patient on Palsonify.
LLY Eli Lilly and Company 85% Reciprocal relationship from LLY graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from LLY grap…
LLY Eli Lilly and Company 85% Radionetics announced the formation of a strategic partnership with Eli Lilly and Company, or Lilly. Under the terms of the agreement, Radionetics received an upfront cash payment of $140 million and…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from CRNX graph: products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-pa…
AZN AstraZeneca PLC 72% products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from NVSE…
NVSEF Novartis AG 72% products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl…
ALEXION-PHARMACEUTICALS-INC-ASTRAZENECA-PLC ALEXION-PHARMACEUTICALS-INC-ASTRAZENECA-PLC 62% products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl…
IPSEN-BIOPHARMACEUTICALS-INC IPSEN-BIOPHARMACEUTICALS-INC 62% products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl…
LEERINK-PARTNERS-LLC LEERINK-PARTNERS-LLC 62% ry for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully devel…
RECORDATI-RARE-DISEASES-INC RECORDATI-RARE-DISEASES-INC 62% products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl…
SANWA-KAGAKU-KENKYUSHO-CO-LTD SANWA-KAGAKU-KENKYUSHO-CO-LTD 62% eighted-average discount rate was 8.6 %. Cash paid for amounts included in the measurement of lease liabilities for operating cash flow from operating leases was $ 4.5 million, $ 1.6 million, and $ 1…
TERSERA-THERAPEUTICS-INC TERSERA-THERAPEUTICS-INC 62% products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl…

Crinetics Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CRNX-DEBT Debt stack $47.9M 90% Market cache reports total debt of $47.9M.
CRNX-DEBT-13804 Warrants outstanding: 3407285 90% xbrl warrant detail from xbrl 2023-08-31.
CRNX-DEBT-8861 Xbrl Convertible 90% xbrl convertible detail from xbrl 2018-12-31.

Crinetics Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Crinetics Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
CRNX-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 245 tracked holders.

Crinetics Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
NVO Novo Nordisk A/S 100.00 2
SLGL Sol-Gel Technologies Ltd. 100.00 2
HTGC Hercules Capital, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
DEO Diageo plc 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
View CRNX supply chain intel →

Explore the full interactive supply chain map for Crinetics Pharmaceuticals, Inc..

Open CRNX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map